Nasal High Flow Therapy for Infants and Children with Acute Hypoxemic Respiratory Failure – a Randomised Controlled Trial

This study aims to conduct a multi-centre trial to assess which infants and children with acute hypoxemic respiratory failure (AHRF) benefit from using Nasal High Flow (NHF) Therapy. For this purpose we will perform a randomised controlled trial comparing current best practice (standard oxygen delivery via subnasal prongs, facemask, venturi mask) versus NHF therapy in children aged 1 – 4 years. With the introduction of this simple to use respiratory system in regional and tertiary centres we aim to investigate if NHF therapy has a lower treatment failure rate in comparison to standard oxygen delivery, and to investigate if there is a reduction in the need for transfer of these patients the intensive care unit.

Study design

A phase III randomised controlled trial

Chief Investigator

A/Prof Andreas Schibler (Queensland Children’s Hospital)


2017 – 2021


Thrasher Research Funds
National Health and Medical Research Council (ID:1123663)
Children’s Health Foundation (LCCH),
Emergency Medicine Foundation

Site locations

  • Lady Cilento Children’s Hospital, Brisbane, QLD, Australia
  • Royal Children’s Hospital, Melbourne, Australia
  • Gold Coast Hospital, Southport, Queensland, Australia.
  • Starship Children’s Hospital, Auckland, New Zealand
  • KidzFirst Middlemore Hospital, Auckland, New Zealand
  • Redcliffe Hospital, Redcliffe, QLD, Australia
  • Prince Charles Hospital, Chermside, QLD, Australia
  • Sunshine Coast University Hospital, Sunshine Coast, QLD, Australia
  • Logan Hospital, Logan, QLD, Australia
  • Ipswich Hospital, Ipswich, QLD, Australia
  • Redland Hospital, Cleveland, QLD, Australia
  • Toowoomba Hospital, Toowoomba, QLD, Australia
  • The Tweed hospital, Tweed Heads, NSW, Australia
  • Monash Children’s Hospital, Clayton, VIC, Australia
  • Townsville Hospital, Townsville, Queensland, Australia
  • The Children’s Hospital at Westmead, Sydney, NSW, Australia
  • Caboolture Hospital, Caboolture, QLD, Australia
  • Perth Children’s Hospital, Perth, WA,  Australia
  • John Hunter Hospital, Newcastle, NSW, Australia


1634 children aged 1 – 4 years + 364 days with AHRF

Clinical trial registrations

Click here